EAACI Congress 2024
BackFT 26 - Flash talks on Biologicals
Monday 03 Jun, 12:45 PM -
14:15 PM Valencia, Spain
Cordoba
Flash Talks
12:45
AK006 Drives Mast Cell Anergy as a Result of Antibody Binding Location and Distinct Protein Interaction Network
12:52
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Stapokibart in Healthy and Atopic Dermatitis Adult Subjects
12:59
Decoding Asthma Therapies: Transcriptomic differences between benralizumab and mepolizumab treatment in patients with severe eosinophilic asthma
13:06
Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study
13:13
A single dose of a combination of Bet v 1 antibodies provides durable efficacy in the reduction of allergic rhinitis symptoms for up to 3 months in patients with moderate-severe birch pollen allergy
13:20
Immunodeficiency spectrum in patients with severe asthma receiving biologicals
13:27
Impact of mepolizumab on exacerbations and maintenance OCS use in patients with asthma and baseline blood eosinophil counts of ≥150–<300 cells/μL in the REALITI-A study: 2-year outcomes
13:34
Garadacimab provides early onset of protection against HAE attacks from Week 1 after first administration
13:41
OverSEA: European Delphi Consensus Study on Best Practices for patients with Severe Eosinophilic Asthma and comorbid CRSwNP
13:48
Dupilumab dose reduction in controlled severe atopic dermatitis and predictive factors
13:55
The association between baseline IgE levels and response to standard-dose omalizumab in uncontrolled chronic urticaria patients
14:02
Exploring the controversy and pathogenesis of Topical Steroid Withdrawal Syndrome
